2806
Shares / Re: Pulverized Sand Box
« on: March 25, 2015, 03:59:16 pm »
Weekly Port Analysis
OCE -
AVL -
APN -
NPN -
OCE -
AVL -
APN -
NPN -
Show Posts
This section allows you to view all posts made by this member. Note that you can only see posts made in areas you currently have access to.
2807
Shares / Re: Long Term Portfolios.
« on: March 25, 2015, 09:20:41 am »
INTERNATIONAL BUSINESS
Revenue in the International business was 158% higher at R8.8 billion and performance was boosted by the inclusion of the significant transactions completed during the previous financial year.
Revenue from the Europe CIS business climbed 229% to R5.1 billion from finished dose form pharmaceuticals and active pharmaceutical ingredient sales.
Revenue in Latin America advanced 118% to R2.6 billion, largely driven by the recent infant milk formula acquisition, while sales to customers in the Rest of the World were up 36% to R0.9 billion.
Capital expenditure projects are continuing at Aspen Oss in the Netherlands and at the French-based Aspen Notre Dame de Bondeville site.
ASIA PACIFIC BUSINESS
Revenue in the Asia Pacific region was 3% higher at R4.4 billion where the Nutritionals products led the way with strong double-digit growth. Sales to customers in Asia continued on an impressive growth trajectory, doubling to R0.6 billion.
SOUTH AFRICAN BUSINESS
As the ongoing leading pharmaceutical manufacturer in the country, revenue in the South African business grew by 12% to R4.3 billion. Private sector pharmaceutical sales increased 10% through a combination of organic growth and new product launches. Sales in the public sector were flat. The consumer division raised revenue by 30%, led by the Nutritionals products with Infacare achieving an increase in its share of this category.
The capital expenditure projects at the Port Elizabeth finished dose form manufacturing site and the Cape Town API manufacturing site are progressing well.
SUB-SAHARAN BUSINESS
In Sub-Saharan Africa, revenue improved by 5% to R1.5 billion. Margin improvement initiatives yielded positive results and lifted EBITA 12% to R210 million.
Revenue in the International business was 158% higher at R8.8 billion and performance was boosted by the inclusion of the significant transactions completed during the previous financial year.
Revenue from the Europe CIS business climbed 229% to R5.1 billion from finished dose form pharmaceuticals and active pharmaceutical ingredient sales.
Revenue in Latin America advanced 118% to R2.6 billion, largely driven by the recent infant milk formula acquisition, while sales to customers in the Rest of the World were up 36% to R0.9 billion.
Capital expenditure projects are continuing at Aspen Oss in the Netherlands and at the French-based Aspen Notre Dame de Bondeville site.
ASIA PACIFIC BUSINESS
Revenue in the Asia Pacific region was 3% higher at R4.4 billion where the Nutritionals products led the way with strong double-digit growth. Sales to customers in Asia continued on an impressive growth trajectory, doubling to R0.6 billion.
SOUTH AFRICAN BUSINESS
As the ongoing leading pharmaceutical manufacturer in the country, revenue in the South African business grew by 12% to R4.3 billion. Private sector pharmaceutical sales increased 10% through a combination of organic growth and new product launches. Sales in the public sector were flat. The consumer division raised revenue by 30%, led by the Nutritionals products with Infacare achieving an increase in its share of this category.
The capital expenditure projects at the Port Elizabeth finished dose form manufacturing site and the Cape Town API manufacturing site are progressing well.
SUB-SAHARAN BUSINESS
In Sub-Saharan Africa, revenue improved by 5% to R1.5 billion. Margin improvement initiatives yielded positive results and lifted EBITA 12% to R210 million.
2808
Shares / Re: Today's Outlook
« on: March 25, 2015, 08:38:45 am »
S&P 500 Futures 2,084.95 -0.05 0.00%
Nasdaq Futures 4,431.20 +2.20 +0.05%
Dow 30 18,011.14 -104.90 -0.58%
S&P 500 VIX 13.62 +0.21 +1.57%
DAX 12,005.69 +109.85 +0.92%
Nikkei 225 19,746.20 +32.75 +0.17%
0700.HK -0.42%
NPSNY +1.94%
MAIL.IL +1.50%
New High
WILDRNESS
CONDUIT
CAPITEC
STANBANK
PSG
NETCARE
RESILIENT
LIB-HOLD
SANLAM
New Lows
CARTRACK
AQUARIUS
Nasdaq Futures 4,431.20 +2.20 +0.05%
Dow 30 18,011.14 -104.90 -0.58%
S&P 500 VIX 13.62 +0.21 +1.57%
DAX 12,005.69 +109.85 +0.92%
Nikkei 225 19,746.20 +32.75 +0.17%
0700.HK -0.42%
NPSNY +1.94%
MAIL.IL +1.50%
New High
WILDRNESS
CONDUIT
CAPITEC
STANBANK
PSG
NETCARE
RESILIENT
LIB-HOLD
SANLAM
New Lows
CARTRACK
AQUARIUS
2818
Shares / Re: Naspers (NPN)
« on: March 19, 2015, 04:29:46 pm »
I thought u had NPN and u bought at R800, my portfolio is 48% NPN, bought at R1257 & R1678. But I need to take tablets more often, I was under the impression you kinda introduced me to NPN ?
